Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Clinical trials sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, explained in plain language.
A biopharmaceutical company focused on CAR T-cell therapies for cancer, now part of Bristol-Myers Squibb.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could CAR t cells tame autoimmune brain diseases? Results expected Jul 2027 (estimated)
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Not yet recruitingThis study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …
Phase 3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take on rare blood disorders
Disease control Not yet recruitingThis phase 2 trial tests a personalized CAR T cell therapy called zolacabtagene autoleucel in 52 adults with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The treatment uses the patient's own immune cells, modified to target and destroy faulty B cel…
Phase 2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC